Plasma-SeqSensei™ Kits

Ultra-sensitive NGS liquid biopsy kit solutions

With more than 10 years of experience in liquid biopsy, Sysmex Inostics is propelling liquid biopsy solutions forward with a new next-generation sequencing-based assay: the Plasma-SeqSensei* kit.

Built on ultra-sensitive Plasma-Safe-SeqS technology, the new Plasma-SeqSensei kit portfolio detects and identifies mutations in various genes in human circulating cell-free DNA isolated from blood plasma**.

Plasma-SeqSensei kits provide narrow panels with ultra-high sensitivity down to 0.06% mutant allele fractions (MAF) and absolute limit detection of 6 mutant molecules (MM) which is important for the clinical research purpose such as response monitoring, recurrence monitoring, and minimal residual disease detection.


*Currently only available in EMEA region

**For research use only. Any in vitro diagnostics purpose has not been established by the manufacturer

Citations

*Currently only available in EMEA region

**For research use only. Any in vitro diagnostics purpose has not been established by the manufacturer

Kit Products

Unique Benefits


This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

  • Highly sensitive
    • Detects 0.06% and higher MAF with 95% certainty (in a background of 10,000 wildtype copies)
    • Determines mutant molecules (MM) down to a limit of detection of 6 (independent of real sample DNA input)


This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

  • Absolute quantification of samples using internal quantifier
  • Usage of UIDs (unique molecular identifiers)
    • Reduces error reporting rate over 100-fold
  • Standardized workflow and high reproducibility


This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

  • High flexibility and efficiency
    • Processes 2 to 16 samples per run
    • Pools multiple PSS RUO libraries in one run to save time and sequencing costs (not available for IVD kits)
  • Short turnaround time
    • Takes ~2 days for 16 samples from plasma preparation to results (including sequencing time)


This chart measures the mutant allele frequency of Plasma-Safe-SeqS with OncoBEAMTM  technology for ESR1, PIK3CA, AKT1, ESR1, PIK3A, and AKT1 clinical samples and shows that Plasma-Safe-SeqS has a 99.2 percent positive agreement out of 100 for mutant allele frequency, also known as MAF, sensitivity.

  • Easy-to-use and convenient Plasma-SeqSenseiTM Software
    • Integrates run-planning feature
    • Provides sample variant call file, including validity checks for sample results
    • Automates data analysis and generation of PDF-report per sample

Plasma-SeqSensei™

CRC RUO kit

Highly sensitive detection and identification of mutations in KRAS, NRAS, BRAF, and PIK3CA genes associated with colorectal cancer.

Learn More

Plasma-SeqSensei™

BC RUO kit

Highly sensitive detection and identification of mutations in AKT1, ERBB2, ESR1, KRAS, PIK3CA, and TP53 genes associated with breast cancer.

Learn More

Plasma-SeqSensei™

NSCLC RUO kit

Highly sensitive detection and identification of mutations in BRAF, EGFR, KRAS, and PIK3CA genes, which play a significant role in the development of NSCLC.

Learn More

Plasma-SeqSensei™

Melanoma RUO kit

Highly sensitive detection and identification of mutations in BRAF and NRAS oncogenes associated with melanoma development.

Learn More

Plasma-SeqSensei™

Thyroid RUO kit

Highly sensitive detection and identification of mutations in hotspot regions of BRAF and NRAS genes associated with thyroid cancer.

Learn More

News & Events

The latest

Visit our resource center

Visit our resource center